EUVIMEDEUVIMED entdecken
Crossref

In Brief: Expanded Access to Mifepristone

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1670c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Abortion, Induced, Misoprostol, Abortifacient Agents, Nonsteroidal, Abortifacient Agents, Steroidal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, InducedMisoprostolAbortifacient Agents, NonsteroidalAbortifacient Agents, SteroidalHumansFemalePregnancyMifepristoneDrug Therapy, Combination

Stichwörter der Autor:innen

Mifeprexdosagemifepristonemisoprostol

Substanzen

MifepristoneMisoprostolAbortifacient Agents, NonsteroidalAbortifacient Agents, Steroidal

Zitieren

APA

(2023). In Brief: Expanded Access to Mifepristone. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670c

Vancouver

In Brief: Expanded Access to Mifepristone. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670c

BibTeX
@article{euvimed2023,
  title = {In Brief: Expanded Access to Mifepristone},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1670c}
}
Kostenlos starten →